VivoSeq
Infectious Disease

Rabies

2

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Rabies is an early-stage landscape with 2 programs across 4 companies. The most active players are Synermore Biologics Co., Ltd., Synermore Biologics (Suzhou) Co., Ltd., Novartis.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Synermore Biologics Co., Ltd.

1 program

Phase 2S

Synermore Biologics (Suzhou) Co., Ltd.

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2C

Changchun BCHT Biotechnology Co.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

SYN023

Synermore Biologics (Suzhou) Co., Ltd.

Rabies Vaccine

Novartis

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

3

clinical trials

Not yet recruiting1 · 33%
Unknown status1 · 33%
Completed1 · 33%

Clinical Trials

Trial Activity

Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.
Not yet recruiting·IInstitute of Tropical Medicine, Belgium·Phase 3·NCT07455318·561 enrolled
Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1
Unknown status·CChangchun BCHT Biotechnology Co.·Phase 1·NCT05832073·152 enrolled
A Phase 2b Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Different Rabies Exposure Risks
Completed·SSynermore Biologics Co., Ltd.·Phase 2·NCT03961555·448 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)